Posts

Posted on

Keysight to Demonstrate End-to-End Solutions for Scaling AI Infrastructure at ECOC 2026

Keysight to Demonstrate End-to-End Solutions for Scaling AI Infrastructure at ECOC 2026

SANTA ROSA, Calif.–(BUSINESS WIRE)–
Keysight (NYSE: KEYS):

What: At ECOC 2026, Keysight Technologies will demonstrate solutions that help engineers design, characterize, validate, benchmark, and scale the high-speed optical and AI infrastructure required for next-generation data centers. Highlights will span photonic design and characterization, AI infrastructure and interconnect validation, next-generation optical research, 1.6T optical validation and production test.

When: September 21–23, 2026

Where: Keysight booth #1154, FYCMA, Málaga, Spain

More information: Keysight at ECOC

Keysight experts will showcase solutions to:

  • Accelerate photonic design and characterization: Connect photonic simulation with automated PIC test and 220 GHz characterization to bridge the gap between design, validation, and high-volume manufacturing.
  • Advance next-generation optical links: Explore 3.2T optical research and 1.6T transmitter and receiver validation to reduce design uncertainty and accelerate optical link development.
  • Validate AI infrastructure: Validate high-speed AI and data center interconnects, benchmark AI fabric performance, emulate real-world workloads, and test AI transport and inference at scale.
  • Scale 1.6T production: Combine high-speed optical measurement with automated interconnect validation to minimize test time, optimize yield, and accelerate production ramps.
  • Explore AI-enabled test automation: See how AI and intelligent automation simplify photonics test development, troubleshooting, and data analysis.

About Keysight Technologies

Keysight (NYSE: KEYS) serves technology innovators as a mission-critical design enablement partner for the world’s most complex engineering challenges. By connecting market-leading design, emulation, and test solutions across the full life cycle, Keysight helps engineering teams accelerate innovation, reduce risk, and bring new technologies to market faster. Customers across AI infrastructure, communications, industrial automation, aerospace and defense, automotive, semiconductor, and general electronics rely on Keysight to bridge virtual design and physical reality, enabling confident decisions earlier. Learn more at www.keysight.com.

Keysight Media Contacts

Andrea Mueller

Americas

[email protected]

Fusako Dohi

Asia

[email protected]

Jenny Gallacher

Europe

[email protected]

KEYWORDS: California Europe Spain United States North America

INDUSTRY KEYWORDS: Software Networks Hardware Artificial Intelligence Data Management Engineering Technology Manufacturing

MEDIA:

Logo
Logo
Posted on

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study

  • Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile
  • Clinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological difference
  • Cue Biopharma to host conference call on Monday, September 21, at 8:00 a.m. EDT

BOSTON, Sept. 20, 2026 (GLOBE NEWSWIRE) — Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced positive topline results from the Phase 2 clinical trial of CUE-221 (UB-221) conducted in China by Genesis Life Sciences, a related company of Ascendant Health Limited (Ascendant). The trial enrolled 145 participants with moderate to severe chronic spontaneous urticaria (CSU), a disease resulting in chronic hives, that remained inadequately controlled despite treatment with H1 antihistamines.

“We are excited to share these positive results which we believe establish CUE-221 as a potential best therapeutic option for patients suffering with chronic spontaneous urticaria,” said Shao-Lee Lin, M.D., Ph.D., President and Chief Executive Officer of Cue Biopharma. “These findings reinforce our enthusiasm for the precision engineered, unique dual mechanism of action of CUE-221, reflecting science that is truly differentiated. Based on the strength of these data, we are working toward the rapid initiation of a Phase 2b/3 study in CSU and continuing to advance a planned Phase 2 study in food allergy. We thank the patients, investigators, and study staff, all of whom made these results possible. We look forward to presenting the complete data set including PK and IgE analyses from this 36-week study at an upcoming scientific meeting.”

Phase 2 CSU Study Topline Results

The Phase 2 multicenter, randomized, double-blind, placebo and active comparator-controlled study was conducted in China and included a 16-week treatment period with a 20-week follow-up period post-treatment. Patients were randomized in a 2:2:2:1:1 ratio across five treatment groups to either subcutaneously deliver CUE-221 at 4 mg/kg, 2 mg/kg, or 1 mg/kg Q4W, or placebo Q4W, or omalizumab 300 mg Q4W. The primary endpoint was the proportion of patients who achieved HSS7=0 at week 12. A key secondary endpoint assessed complete response, defined as the proportion of patients who achieved UAS7=0 at week 12. The study was designed to test superiority over placebo. Omalizumab was included to enable comparative efficacy without planned statistical testing.

The primary endpoint of percentage of patients with HSS7=0 at week 12 was dose-responsive and met at all dose levels. The key secondary endpoint of percentage of patients with UAS7=0 at week 12 was dose responsive and met statistical significance at the 4 mg/kg highest dose level.

Primary Endpoint of HSS7=0 at Week 12
  CUE-221 (Q4W) Placebo Q4W Omalizumab Q4W
  4 mg/kg (N=35) 2 mg/kg (N=36) 1 mg/kg (N=37) (N=18) 300 mg (N=17)
Complete Resolution of Hives (HSS7=0) 54% 53% 43% 11% 41%
95% Confidence Interval (37%, 71%) (36%, 70%)  (27%, 61%) (1%, 35%) (18%, 67%)
P-values (vs placebo) p < 0.005 p < 0.005 p < 0.05 NA Not Tested

P-values based on Fisher’s exact test; Clopper-Pearson 95% confidence interval

Key Secondary Endpoint of UAS7=0 at Week 12
  CUE-221 (Q4W) Placebo Q4W Omalizumab Q4W
  4 mg/kg (N=35) 2 mg/kg (N=36) 1 mg/kg (N=37) N=18 300 mg (N=17)
Complete Response (UAS7=0) 46% * 39% 38% 11% 29%
95% Confidence Interval (29%, 63%) (23%, 57%) (23%, 55%) (1%, 35%) (10%, 56%)

* p<0.05 P-values based on Fisher’s exact test; Clopper-Pearson 95% confidence interval

The percentage of participants who achieved HSS7=0 further increased beyond the Week 12 primary endpoint, peaking at Week 22 across all CUE-221 dose groups. After a last dose was administered for all groups at Week 16, clinically meaningful benefit was maintained for up to 12 weeks off treatment (through week 28) at the 4 mg/kg dose level. A higher rate of complete resolution of hives was observed for the 4 mg/kg dose group relative to the lower dose groups and placebo, and post hoc analysis at Week 28 demonstrated a statistically significant difference versus omalizumab (delta = 36%), supporting the premise of fundamental difference between CUE-221 and omalizumab with respect to impacts on disease biology.

Complete Resolutions of Hives at Primary Endpoint, Peak Effect, and 12 Weeks Off Drug
  CUE-221 (Q4W) Placebo Q4W Omalizumab Q4W CUE 4mg/kg vs.Omalizumab
Time 4 mg/kg 2mg/kg 1 mg/kg Placebo 300 mg Δ in Percent
Week 12 Primary 54% 53% 43% 11% 41% 13%
Week 22 Peak Effect 69% 61% 57% 11% 41% 28%
Week 28 12 weeks off drug 60% 31% 24% 11% 24% 36% *

* p<0.05 P-values based on Fisher’s exact test

Demographics and baseline disease characteristics were generally well balanced across treatment groups. CUE-221 demonstrated a favorable safety profile. There were no treatment-related serious adverse events and no cases of hypersensitivity reactions including anaphylaxis. Injection site reactions (ISR) were infrequent, only one ISR was > grade 1, and none led to study discontinuation.

“The results of the Phase 2 CUE-221 study in patients with CSU are particularly notable,” said Dale Umetsu, M.D., Ph.D., Clinical Professor of Medicine and former Chief of the Allergy and Immunology Division, Stanford University, Clinical Professor of Pediatrics, University of California, San Francisco and prior Global Lead for XOLAIR development. “First, the results after 12 weeks of treatment, after three doses, appear to indicate that CUE-221 was better than XOLAIR for CSU at all dose levels tested. Moreover, there was persistent improvement with the 4 mg/kg dose at week 28, which was 12 weeks off treatment, significantly better than that off of standard XOLAIR dosing. Finally, the safety data analyzed so far, show no major safety issues, which is not unexpected from an anti-IgE mAb.”

Dr. Umetsu added, “These results suggest that CUE-221, like XOLAIR is designed to prevent IgE from binding to FceR1 but unlike XOLAIR, allows IgE to bind to CD23, may represent a critical advancement over XOLAIR. The results support that the effects of CUE-221 on IgE function could result in substantial efficacy in CSU that persists for several months, even after dosing ends. Since XOLAIR has represented the clear standard for all other CSU therapies, the possibility that CUE-221 may represent a clear improvement above that of XOLAIR is most impressive. That improvement in efficacy may be directly relevant for food allergy, another area where XOLAIR currently prevails as the standard-of-care.“

“I am very pleased to see these outstanding results from the UB-221 Phase 2 CSU trial,” said Tse-Wen Chang, Ph.D., innovator of XOLAIR as well as UB-221 and an international expert in IgE biology. “The UB-221 data provide clear clinical evidence validating the molecule’s design to not only directly neutralize IgE, but also to create a next-generation approach to eliminate the production of new IgE over time. This fundamental difference in biological mechanism that is now clinically evident cannot be reached by giving higher doses or more potent IgE neutralization. Having invented several novel IgE-targeting molecules that ultimately led to the creation of UB-221, I am encouraged by these emerging data and the potential for this approach to offer a meaningfully different path toward a functional treatment for IgE-mediated diseases.”

Webcast and Conference Call

Cue Biopharma will host a conference call and webcast on Monday, September 21 at 8:00 a.m. EDT to present the results. The event will be webcast live and can be accessed via the attached link below. https://edge.media-server.com/mmc/p/mjexxy37 

About Dale Umetsu, M.D., Ph.D.

Dale Umetsu, M.D., Ph.D., Former chief of the allergy immunology division and tenured professor of pediatrics at Stanford University, and Former Prince al Saud Professor of Pediatrics AT Harvard Medical School. Dr. Umetsu also led global development of XOLAIR and the approval of XOLAIR for CSU and food allergy while at Genentech. Currently, he serves as a clinical professor of pediatrics at the University of California, San Francisco.

About Tse-Wen Chang, Ph.D.

Tse-Wen Chang, Ph.D., is a Taiwanese immunologist and pioneer in anti-IgE therapy. His early research into the immunoglobulin E (IgE) pathway and antibody-based therapeutics contributed to the development of omalizumab (XOLAIR), which is approved for the treatment of severe allergic asthma and severe chronic spontaneous urticaria. Dr. Chang is a cofounder of Tanox, a biopharmaceutical company focused on anti-IgE therapies for allergic diseases. He previously served as Dean of the College of Life Sciences at National Tsing Hua University in Taiwan and as Distinguished Research Fellow at the Genomics Research Center, Academia Sinica.

About Chronic Spontaneous Urticaria

CSU is a chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch. CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control symptoms of itch and urticaria. However, the disease remains uncontrolled despite antihistamine treatment in many patients, some of whom are left with limited alternative treatment options. These individuals continue to experience symptoms that can be debilitating and significantly impact their quality of life.

About CUE-221

CUE-221 (Ascendant-221, UB-221) is a humanized anti-IgE IgG1 monoclonal antibody designed with a precision engineered dual mechanism of action. CUE-221 binds to IgE at sites that are distinct from the binding sites for other anti-IgE monoclonal antibodies. In doing so, it maintains the capacity of total IgE to bind the CD23 receptor at the surface of B cells, resulting in reduced IgE synthesis. Therefore, CUE-221 is a functionally distinct novel anti-IgE antibody designed to not only neutralize free IgE with high potency, but also prevents the synthesis of new IgE which could ultimately result in functional cure if IgE is eradicated. The CUE-221 Phase 2 clinical trial in CSU produced positive topline results and clinical evidence providing initial validation of the clinical potential of a precision engineered anti-IgE dual mechanism of action. The study also demonstrated fundamental biological differences compared to current therapies. Based on these data, we are planning to advance CUE-221 in a Phase 2b/3 study in chronic spontaneous urticaria and in a Phase 2 study in food allergy.

CUE-221 (UB-221) was innovated by Dr. Chang Tse Wen, a pioneer in the field of anti-IgE therapy, while serving as a Fellow of Academia Sinica. UB-221 was originally developed by United Biopharma (Holdings) Co., Ltd. (“United Biopharma”) with rights allocated between two of United Biopharma’s related companies, Genesis Life Sciences (“Genesis”) (China, Hong Kong, Macau and Taiwan, where Genesis continues development of the antibody under the name UB-221) and Ascendant Health Limited (“Ascendant”) (rest of world). Under an exclusive license agreement with Ascendant, Cue Biopharma obtained exclusive development, manufacturing, and commercialization rights in Ascendant’s rest of world territories.

About Cue Biopharma

Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies designed to enable functional cures across immunological disorders. Its lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action design, moving into Phase 2b/3 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, has an investigational new drug application pending in the U.S. for a Phase 1 clinical trial. CUE-401 is designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.

About Ascendant Health Limited

Ascendant is a privately held biotechnology company committed to delivering transformative solutions to patients globally.

About Genesis Life Sciences

Genesis Life Sciences focuses on the innovative development of monoclonal antibody drugs. It is a biopharmaceutical company with a product line in late-stage clinical trials, specializing in the development of innovative monoclonal antibody drugs applicable to chronic infectious diseases, allergic diseases, and autoimmune diseases. Closely aligned with key national research projects and market demand, the company has introduced highly promising monoclonal antibody products, leveraging internal research capabilities and support from expert teams across various fields to accelerate the product launch and sales process. We care about human health and well-being, focus on unmet patient needs, and drive monoclonal antibody development through innovative thinking, ultimately sharing our results with partners and the public, striving to provide the best treatment for patients.
*XOLAIR® is a registered trademark of Novartis AG.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding the potential of CUE-221, including its potential future benefit to patients, the company’s plans with respect to CUE-221, including the initiation of a Phase 2b/3 clinical trial in CSU and a Phase 2 clinical trial in food allergy and the timing thereof, the company’s expectations regarding the presentation of full clinical data from the Phase 2 CUE-221 trial, the company’s growth, and the company’s business strategies, plans, and prospects.

Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise,” “potential” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to maintain and establish collaboration, licensing and other arrangements; the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts for its current and future drug product candidates, including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; potential challenges associated with clinical trials conducted in China and the company’s access to, and acceptability of, the data therefrom; its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. 

Investor and Media Contact

Agnes Lee
Chief Investor Relations & Communications Officer
[email protected]

Marie Campinell
Senior Director, Corporate Communications

[email protected]

Cue Biopharma, Inc.



Posted on

ENVA Investors Have Opportunity to Join Enova International, Inc. Fraud Investigation with SBS Law

ENVA Investors Have Opportunity to Join Enova International, Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enova International, Inc. (“Enova” or “the Company”) (NYSE: ENVA) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Enova revealed on September 14, 2026, that it had withdrawn its applications for the proposed acquisition of Grasshopper Bancorp, Inc. (“Grasshopper”). The Company stated, “we are confident that withdrawing our applications is the best decision for Enova and our shareholders.” However, during the Company’s July 2026 earnings call, CEO Steve Cunningham said, “I have a lot of confidence in our application. I have a lot of confidence in the process, and I look forward to closing later this year.” Based on this news, shares of Enova fell by 23.4% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990

Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990

  • FF launched four Industry Productivity Solutions across K-12 Education, Research, Security and Inspection, helping customers reduce deployment and adoption barriers and providing industries with replicable paths to practical robot applications aiming to deliver the industry’s highest-ROI solutions.

  • FF launched nine new EAI Device configurations across two robot forms, three product series and five models: FF All-New Futurist, FF Master Mini, FX Aegis Hyper, FX Aegis Mega and FX Aegis Classic Ultra-W. All nine products are now available for sale and delivery.

  • FF aims to build the world’s only “One-Brain Multi-Form Multi-Capability” FF EAI Robot World, with Version 2.0 now complete. FF believes it has become the U.S. robotics company with the most complete range of robot forms, the broadest size coverage and the largest number of robot models.

  • FF has established a “Light on Four, Heavy on Four” operating model, remaining light on capital, assets, marketing and sales while focusing on product strength, AI, real-world utility and users to improve the efficiency of strategy execution. Based on the Company’s Q2 financial results, the average contribution margin on its robotics products reached approximately 30%.

  • FF Master Mini starts at $9,990 and is North America’s first compact EAI humanoid robot priced below $10,000 to combine programming education, open development and sports competition. Both FX Aegis Mega configurations are priced at $74,990 and offer exceptional value among mid-sized industrial robot dogs in the U.S. market. FF’s goal is to combine “the lowest price, four-core value and ongoing service” in a complete, high-value “Four-Core Full-Stack AI” EAI ecosystem.

  • FF has established its “6+1” FF EAI Robotics Direct Sales and Robot-Sharing Rental Network, with six routes to market: B2B, FF Par, E-commerce, Marcom & Video Sales, Community and Mcube. RoboShare provides additional options for rentals and asset onboarding.

  • RoboShare, the robot-sharing and rental platform of AIxC which is majority-owned and controlled by FF, has signed an MOU with Hifivebot, a U.S. robot rental platform. RoboShare is also evaluating an expansion of its existing network into additional AI device categories, including autonomous shared mobility, to explore broader Physical AI asset-sharing services.

  • FF plans to hold an FF EAI Robotics partnership launch in the Middle East with local partners on September 23. On September 28, FF plans to hold Part Two of the FF EAI Robotics “Built in USA” Launch and Business Partner Conference. FF will also participate in IROS 2026 in Pittsburgh from September 28 through September 30.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today held its 919 FF EAI Robotics “Four-Core Full-Stack AI” Ecosystem New Product Series Launch. FF unveiled 9 new EAI Device configurations across five models which included its FF All-New Futurist, FF Master Mini, FX Aegis Hyper, FX Aegis Mega and FX Aegis Classic Ultra-W. FF also launched 4 Industry Productivity Solutions for K-12 Education, Research, Security and Inspection. FF’s “Four-Core Full-Stack AI” open ecosystem comprises the EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and the EAI Data Factory. The event highlighted the latest product and application developments across the EAI Devices and Industry Productivity Solutions cores.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260919657129/en/

Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990

Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990

A video of the event can be viewed here: https://youtu.be/0KZGgyrsUcU

“FF is not building a single robot form that attempts to do everything, we are building a robotics ecosystem in which a generalized and adaptable EAI Brain supports multiple robot forms,” said YT Jia, Founder and Global CEO of FF. “Our approach aligns with renowned AI scientist and Stanford professor Dr. Fei-Fei Li’s view that multiple robot forms will coexist within one ecosystem. These robot forms not only address a wider range of tasks but also generate real-world data from diverse scenarios and interactions. Through the EAI Data Factory, that data supports EAI Brain training, Skills development and EAI Device iteration, enabling robot forms and capabilities to evolve together.”

Five Models and Nine New EAI Devices Complete FF’s EAI Robot World 2.0

The nine new EAI Device configurations span two robot forms, humanoid and quadruped, and three product series.

FF All-New Futurist is positioned as a flagship, full-size professional EAI humanoid robot and an “All-in-One Professional Expert.” It has 51 active degrees of freedom, increasing to 71 with an advanced dexterous-hand upgrade. Its 1,152-watt-hour dual-battery system supports approximately eight hours of operation under standard working conditions, along with autonomous charging. The Ultra version is powered by NVIDIA Jetson Thor and delivers 700 TOPS of computing power. Combined with VLA, world models, and task planning, it can move beyond executing individual commands to complete entire tasks. The product is designed for university research, embodied AI development, enterprise services, sports competition, and industrial applications. The FF All-New Futurist Standard is priced at $89,900 and includes a Skills Package valued at $10,000. The FF All-New Futurist Ultra is priced at $129,900 and includes a Skills Package valued at $15,000.

The FF Master Mini including three configurations, Master Mini, Master Mini Pro, and Master Mini Ultra, is positioned as an EAI humanoid robot for education, sports and robotics competition, serving as an all-rounder “from classroom to competition.” It stands approximately 95 centimeters tall and weighs approximately 19.5 kilograms. Its three configurations provide 48, 117, and 200 TOPS of computing power, respectively. Open motion, perception and application interfaces support programming education, open development, entertainment performances, and robot soccer competitions. The Master Mini series starts at $9,990 and includes a Skills Package valued at $1,000. The Pro version is priced at $12,990 and includes a Skills Package valued at $1,500. The Ultra version is priced at $17,990 and includes a Skills Package valued at $2,000.

FX Aegis Hyper is a large industrial-grade EAI quadruped designed for extreme environments, heavy-duty tasks and high-risk autonomous operations, with support for professional payloads including thermal imaging, gas detection, 3D scanning and communications relay equipment. The Aegis Hyper starts at $137,900 and includes a Skills Package valued at $15,000.

FX Aegis Mega, available in two configurations, is mid-sized industrial-grade wheel-legged EAI robots with a maximum payload capacity of 50 kilograms. They can continuously climb 25-centimeter stairs and clear single obstacles up to 80 centimeters, while hot-swappable dual batteries provide at least five hours of unloaded runtime. The Aegis Mega starts at $74,990, including an $8,000 Skills Package.

FX Aegis Classic Ultra-W is a lightweight professional wheel-legged EAI robot for security and companionship. Its approximately 22-kilogram body combines wheeled mobility, legged obstacle-clearing capability, low-noise operation and open development, with support for secondary development, simulation training, multi-robot coordination and professional payload expansion. The Aegis Classic Ultra-W is priced at $12,990, including a $3,000 Skills Package.

With the launch of these nine new configurations, FF EAI Robot World has officially been upgraded to Version 2.0. The portfolio now covers three robot forms, humanoid, quadruped and mobile manipulator; five product series, Futurist, Master, Aegis, Navi and Faber; 11 models; and 24 products.

Four Industry Productivity Solutions and FF EAI Robotics Education & Research Ecosystem 1.0

FF launched four EAI Robotics Industry Productivity Solutions for K-12 Education, Research, Security and Inspection. The K-12 Education and Research Solutions together form the FF EAI Robotics Education & Research Ecosystem 1.0. The Security and Inspection Solutions address communities, buildings, industrial parks, energy, electric power, manufacturing, mining, tunnels and large facilities. With the four Industry Productivity Solutions, FF aims to offer solution pricing designed with the highest ROI in the industry, further lowering deployment and adoption barriers for customers.

The FF EAI Robotics K-12 Education Solution is an integrated Physical AI teaching and competition growth platform for K-12 students. Centered on Master Mini, the solution brings together Navi, Aegis, Master and All-New Futurist to support different stages, from early learning through advanced high-school education and university research. The platform provides a three-tier curriculum in Blockly, Python and ROS, together with a supporting competition system covering early interest, programming, AI practice, robot competition and the progression to research and higher education. The solution also includes robots and development kits, grade-specific courses, teaching and learning platforms, a developer platform, teacher training, classroom and competition projects, device and classroom management, learning assessment, data security and technical support. It provides modular support for K-12 private schools, public schools and school districts, and training institutions.

The FF EAI Robotics Research Solution is a Physical AI teaching and embodied AI research platform for universities that spans multiple robot forms. Led by All-New Futurist, it brings together Master, Master Mini, Aegis Classic, Aegis Mega and Faber. The platform provides a unified SDK, ROS interfaces, simulation and digital twins, data collection, model training and Skill management. It supports research in motion control, embodied foundation models, Sim-to-Real and swarm intelligence, enabling research teams to complete algorithm development, simulation validation, physical robot deployment and cross-device migration within a unified tool chain.

The FF EAI Robotics Security Solution uses a tiered, multi-model deployment approach. The Aegis Classic handles indoor and building patrols, while Aegis Mega handles large outdoor and high-risk tasks. Professional payloads can include thermal imaging, 360-degree cameras and LiDAR. The platform supports multi-robot management, autonomous patrols, multimodal sensing, AI event recognition, alarm integration, remote operation and evidence archiving across communities, campuses, industrial parks, warehouses and critical infrastructure.

The FF EAI Robotics Inspection Solution is designed for energy, electric power, manufacturing, mining, tunnels and large facilities. Aegis Mega handles high-frequency inspections at large industrial parks and power stations, Aegis Hyper operates in extreme and high-risk areas, and Faber performs precision indoor operations. The system supports PTZ cameras, thermal imaging, gas detection, 3D scanning and robotic-arm end effectors. The FF Smart Inspection Platform provides autonomous mapping, meter OCR, anomaly and leak detection, report generation, alerts and work-order management.

Within the “Four-Core Full-Stack AI” open ecosystem, partners can connect with EAI Devices across different robot forms and contribute professional payloads, algorithms, Skills, data and scenario capabilities to jointly develop Industry Productivity Solutions for different sectors.

Sales and Delivery Begin Today; FF Establishes a Unique “6+1” Direct Sales and Robot-Sharing Rental Network

FF offers three product packages: a standard EAI Device, an EAI Device + Skills Package, and an EAI Device + Complete Solution. The Company has also established its “6+1” FF EAI Robotics Direct Sales and Robot-Sharing Rental Network, which means it offers six different routes to market including B2B, FF Par, E-commerce, Marcom & Video Sales, Community and Mcube. Each one covers different customers and sales touchpoints and connects with FF’s unified systems for orders, delivery, pricing and after-sales support. RoboShare, a robot-sharing and operations platform operated by AIxC, which is majority-owned by FF, provides on-demand robot rentals and asset onboarding for eligible devices, further connecting product sales, channel partnerships, asset operations and real-world deployment.

All products are now available for sale and delivery. Customers can place orders through FF.com, Amazon, and RobotShop. Additional product details, including compliance information, are available on FF.com.

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a “Four-Core Full-Stack AI” ecosystem comprising the EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and the EAI Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capabilities, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and advance the development of Physical AI.

For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding Faraday Future Intelligent Electric Inc.’s (the “Company’s”) “Bridge Strategy,” the Company’s growth strategy, fundraising activities and prospects, the development of markets in which the Company operates or seeks to operate, the production and delivery of the FF 91, the Faraday X (FX) brand, and future compliance with Nasdaq listing requirements, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These forward-looking statements speak only as of the date of this press release, and the Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Important factors that may affect actual results or outcomes include, among others: the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy; the willingness of convertible debt investors to fund the Company; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the ability of the Company to expand into additional markets for its robotics products; the Company’s reliance on a single OEM for most of its robotics products; the Company’s reliance on Chinese OEMs for all of its robotics products; the possibility of the federal government banning imports of Chinese robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; the Company’s ability to attract and retain employees; any adverse developments in existing legal proceedings or the initiation of new legal proceedings; and volatility of the Company’s stock price.

You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026; the Company’s Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 14, 2026; the Company’s Form 10-K filed with the SEC on March 31, 2026; and other documents filed by the Company from time to time with the SEC.

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: China United States North America Asia Pacific California

INDUSTRY KEYWORDS: Robotics Education Technology Manufacturing Other Technology Other Education Other Manufacturing

MEDIA:

Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990
Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990
Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990 – (FX Aegis Mega Shown)
Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990 – (FX Aegis Classic Ultra-W Shown)
Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990 – (FX Aegis Mega Shown)
Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990 – (FX Aegis Hyper Shown)
Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990 – (FF All-New Futurist Shown)
Photo
Photo
Faraday Future Launches Four Industry Productivity Solutions, Nine New EAI Devices at Its 919 Event, Building Its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0; All-New Futurist Now on Sale and Master Mini Starts at $9,990 – (FF Master Mini Shown)
Logo
Logo
Posted on

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (“Cellectis” or “the Company”) (NASDAQ: CLLS) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cellectis announced on September 14, 2026, that it would prioritize in vivo gene editing therapies over CAR-T cell therapies. The Company also announced the discontinuation of development of certain CAR-T cell therapies. The Company’s Chief Medical Officer stated, “Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have.” Based on this news, shares of Cellectis fell by almost 41% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

SEDG Investors Have Opportunity to Join SolarEdge Technologies, Inc. Fraud Investigation with SBS Law

SEDG Investors Have Opportunity to Join SolarEdge Technologies, Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of SolarEdge Technologies, Inc. (“SolarEdge” or “the Company”) (NASDAQ: SEDG) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. SolarEdge released its financial results for Q2 2026 on August 5, 2026. The Company forecasted Q3 revenues that fell short of analyst estimates. Based on this news, shares of SolarEdge fell by almost 30.5% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

KLAR Investors Have Opportunity to Join Klarna Group plc Fraud Investigation with SBS Law

KLAR Investors Have Opportunity to Join Klarna Group plc Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Klarna Group plc (“Klarna” or “the Company”) (NYSE: KLAR) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Klarna released its financial results for Q2 2026 on August 18, 2026. The Company significantly lowered its full-year 2026 revenue forecast. The Company also announced the departure of its CFO and CMO in early 2027. Based on this news shares of Klarna fell by more than 22.8% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

BBW Investors Have Opportunity to Join Build-A-Bear Workshop, Inc. Fraud Investigation with SBS Law

BBW Investors Have Opportunity to Join Build-A-Bear Workshop, Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Build-A-Bear Workshop, Inc. (“Build-A-Bear” or “the Company”) (NYSE: BBW) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

DNOW 13-DAY DEADLINE ALERT: DNOW Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 2, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Sept. 19, 2026 (GLOBE NEWSWIRE) — National shareholder rights law firm Hagens Berman encourages investors in DNOW Inc. (NYSE: DNOW) who suffered substantial losses submit your losses now. A securities class action lawsuit has been filed regarding potential violations of federal securities laws involving DNOW’s acquisition of MRC Global Inc. and undisclosed enterprise software integration failures in the merger proxy materials.

  • Lead Plaintiff Deadline: Oct. 2, 2026
  • Defined Investor Class and Record Date: Shareholders who held DNOW common stock as of the August 5, 2025 record date and were thus entitled to vote at DNOW’s September 9, 2025 special meeting on the merger of DNOW and MRC Global

Investors with significant losses are urged to contact the firm to review their options:

Allegedly Misleading Proxy Materials:

The suit alleges that the Proxy Materials misrepresented and omitted to disclose challenges posed with DNOW’s merger with MRC Global Inc. as a result of material issues affecting MRC Global’s new ERP system.

The Truth Allegedly Emerges

  • November 5, 2025 — Reassurances Before Acquisition: The complaint alleges that on DNOW’s Q3 2025 earnings call—the day before closing the merger—management assured investors that MRC Global had implemented a “state-of-the-art” Enterprise Resource Planning (ERP) system that promised “improved inventory management, order processing efficiency, and supply chain optimization.” DNOW allegedly minimized integration risks, reassuring the market that MRC’s past software glitches were merely an “isolated, one-time event.”
  • February 20, 2026 — The Disclosures: DNOW reported its Q4 and full-year 2025 financial results, revealing that MRC revenues had sharply declined due to “persistent ERP challenges” and acknowledging that MRC’s software implementation was, in fact, an “obstacle.”
  • Operational Flaws & Guidance Delay: Management conceded that flawed software design architecture caused severe operational slowdowns, impeded customer service, and required substantial unexpected capital expenditure to remediate. Consequently, DNOW was forced to delay its sequential and full-year 2026 financial guidance.
  • Market Impact: On this news, DNOW stock crashed 19% in a single trading session.

Statement from Hagens Berman Partner Reed Kathrein

“We are focused on whether the Proxy Materials downplayed ERP integration failures at MRC Global allowing management to push the deal through, as the complaint alleges,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the claims in the pending suit.

What DNOW Investors & Whistleblowers Can Do

  • DNOW Investors: If you purchased DNOW common stock and sustained significant losses, you may be eligible to take an active role in the class action. The court-appointed lead plaintiff deadline is October 2, 2026.Submit your loss details here.

  • Whistleblowers: Persons with non-public information regarding DNOW should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]



Posted on

PNR 13-DAY DEADLINE ALERT: Pentair plc Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 2, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Sept. 19, 2026 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP alerts investors in Pentair plc (NYSE: PNR) that a securities fraud class action lawsuit filed against the company has been expanded to cover an earlier class period. Investors who suffered substantial losses are urged to submit their losses now.

CASE DETAILS

Expanded Class Period: March 11, 2025 – July 14, 2026 (Previously April 28, 2026 – July 14, 2026)
Lead Plaintiff Deadline: Oct. 2, 2026
Contact Hagens Berman: Visit www.hbsslaw.com/pnr, email [email protected], or call (844) 916-0895

ALLEGED MISCONDUCT & EXPANDED CLASS PERIOD

The new class action lawsuit alleges that beginning on March 11, 2025, Pentair plc and certain of its top executives made a series of materially false and misleading statements and omitted critical adverse operational information regarding Pentair’s financial health, channel inventory, and internal controls.

Specifically, the lawsuit alleges Defendants failed to disclose that:

  1. Pentair was experiencing severe, undisclosed channel inventory destocking—particularly within its core Pool segment.
  2. The company engaged in unsustainable channel-loading and sales practices with distributors to artificially inflate short-term financial metrics.
  3. As a result, Pentair’s positive statements regarding its business, full-year financial guidance, and operating income lacked a reasonable basis.

THE DISCLOSURE & MARKET REACTION

The complaint alleges that the artificial inflation in Pentair shares came to an abrupt end on July 14, 2026, after the market closed, when Pentair shocked investors by pre-announcing preliminary second-quarter 2026 financial results that fell substantially below consensus estimates.

The disclosures revealed severe operational headwinds:

  • Massive Revenue Miss: Sales were expected to be approximately $930 million—a drastic miss against prior forecasts of $1.14 billion. The company disclosed that inventory destocking in the Pool channel negatively impacted Pool segment sales by approximately $170 million and income by approximately $105 million.
  • Full-Year Guidance Slashed: Pentair dramatically cut its full-year 2026 outlook, reversing earlier projections. Full-year sales were projected to be down approximately 4% to 7%, compared to prior guidance of up 2% to 4% growth.
  • Abrupt CFO Departure: Compounding the shock, Pentair announced the immediate departure of its Chief Financial Officer, Nicholas Brazis, after serving in the role for only four months, raising questions regarding internal controls and financial reporting.

Following these disclosures, Pentair’s stock price plummeted 15% in a single session—losing $11.35 per share to close at $64.33 on unusually heavy trading volume on July 15, 2026.

“We are closely examining the timing of these disclosures, the sudden departure of the CFO after only four months, and the severe impact of channel destocking on Pentair’s financial health,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the alleged claims.

What Affected PNR Investors Should Do

If you purchased or acquired Pentair common stock between March 11, 2025, and July 14, 2026, and suffered significant financial losses, you have until October 2, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/pnr, call Reed Kathrein at 844-916-0895, or email [email protected]. 

If you’d like more information and answers to other frequently asked questions about the Pentair case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Pentair should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]